Related Experiment Video
Updated: Mar 21, 2026
09:21
Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor
Published on: January 4, 2016
10.5K
A Novel FXR-Targeted DUBTAC and Its Applications in Cholestasis Therapy
Ming Cui1,2, Bin Tang1,2, Tingting Yao1,2
1State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210000, P. R. China.
Journal of Medicinal Chemistry
|March 20, 2026
Summary
Researchers discovered D11, a novel compound that stabilizes Farnesoid X receptor (FXR) protein levels. This breakthrough offers a promising new therapeutic strategy for cholestatic liver diseases by preventing protein degradation.
Area of Science:
- Pharmacology
- Hepatology
- Molecular Biology
Background:
- Farnesoid X receptor (FXR) is crucial for treating cholestatic liver diseases.
- FXR agonists often lose efficacy because the receptor degrades under disease conditions.
Purpose of the Study:
- To discover and develop novel FXR stabilizers for cholestasis therapy.
- To investigate a new therapeutic approach by stabilizing FXR instead of activating it.
Main Methods:
- Synthesized 31 novel compounds by linking FXR ligands with an OTUB1 ligand.
- Evaluated compound D11 for its ability to stabilize FXR protein in vitro (HepG2 cells) and in vivo (ANIT-induced cholestasis mouse model).
- Assessed the mechanism of action, requiring a functional ubiquitin-proteasome system.
Main Results:
- Compound D11 significantly increased FXR protein levels in HepG2 cells and in mice with cholestasis.
- D11 demonstrated potent hepatoprotective effects against cholestasis.
- The compound exhibited a favorable safety profile.
Conclusions:
- D11 is a potent FXR deubiquitinase-activating compound (DUBTAC) stabilizer and a promising candidate for cholestasis treatment.
- Stabilizing FXR offers a novel therapeutic avenue for cholestatic liver diseases, overcoming limitations of traditional FXR agonists.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
717
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
717
01:29Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:17Chronic Bowel Disorders: Introduction
893
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
893
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
1.0K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
1.0K
01:17Hepatic Drug Excretion: Enterohepatic Cycling
3.2K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.2K